Sign up for our newsletter


The suPAR biomarker predicts negative patient outcomes by measuring the immune system’s activation level across diseases.

suPARnostic® is a reliable prognostic tool that enables healthcare professionals to make quick and informed patient triaging decisions with confidence, by making better informed decisions across diseases, backed by reliable data.

At hospital emergency departments, suPAR delivers faster and safer patient discharges, reduces readmissions, avoids unnecessary admissions, and lowers hospital length of stay.

Implementing suPAR in clinical care saves critical resources and valuable time, and results in vastly reduced healthcare costs, more efficient triage, and better patient outcomes.

Sign up for our newsletter to get the latest news and publications on suPAR.

Thank you!

You'll hear from us shortly.

An error occured!

Please try again, or contact us by e-mail if the problem persist.

“It has become clear that suPAR is a very strong prognostic marker, exceeding the prognostic value of all other routinely measured biomarkers in our hospital.”

Prof. Ove Andersen,
MD, PhD, DmSc, Copenhagen University Hospital Hvidovre, Denmark
suPAR News Vol. 3, June 2020



1: Thunø M, Macho B, Eugen-Olsen J. suPAR: The molecular crystal ball. Dis Markers. 2009;27(3):157-72.
2: Schultz et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2019, 27:43
3: Eugen-Olsen, J. et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J. Intern. Med. 2010;268, 296–308.
4: Borne Y, Persson M, Melander O,et al. Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure butnotatrial fibrillation. European journal of heart failure 2014;16:377-83.
5: Eapen DJ, Manocha P, Ghasemzedah N,et al. Soluble urokinase plasminogen activator receptor level isan independent predictor of the presence and severity ofcoronary artery disease andof future adverse events. Journal of the American Heart Association 2014;3:e001118.
6: Gumus A, Altintas N, Cinarka H,et al. Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD. International journal of chronic obstructive pulmonary disease 2015;10:357-65.
7: Lyngbaek S, Andersson C, Marott JL, et al. Soluble urokinase plasminogen activator receptor for risk prediction in patients admitted with acute chest pain. Clinical chemistry 2013;59:1621-9.
8: Lyngbaek S, Marott JL, Moller DV, et al. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention. The American journal ofcardiology 2012;110:1756-63.
9: Molkanen T, Ruotsalainen E, Thorball CW, et al. Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2011;30:1417-24.
10: Persson M, Ostling G, Smith G,et al. Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease. Stroke; a journal of cerebral circulation 2014;45:18-23.
11: Raggam RB, Wagner J, Pruller F,et al. Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome. Journal of internal medicine 2014;276:651-8.
12: Hayek S, Sever S,Ko Y et al. Soluble urokinase receptor and chronic kidney disease. N Engl J Med. 2015 Nov 12; 373(20):1916-25.
13: Reichsoellner M, Raggam RB, Wagner J, Krause R, Hoenigl M. Clinical evaluation ofmultiple inflammation biomarkers for diagnosis and prognosis for patients with systemic inflammatory response syndrome. Journal of clinical microbiology 2014;52:4063-6.
14: Suberviola B, Castellanos-Ortega A, Ruiz Ruiz A, Lopez-Hoyos M, Santibanez M.Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission. Intensive care medicine 2013;39:1945-52.
15: Zimmermann HW, Koch A, Seidler S, Trautwein C, Tacke F. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver international : official journal of the International Association for the Study of the Liver 2012;32:500-9.
16: Donadello K, Scolletta S, Taccone FS, et al. Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients. Journal of critical care 2014;29:144-9.

+700

published suPAR studies in leading medical journals

The suPARnostic® brand consists of 3 products:

Photo of The suPARnostic® Quick Triage kit

Quick Triage

A Point of Care Solution

Photo of suPARnostic® TurbiLatex

TurbiLatex

For Automated Systems

Photo of suPARnostic® ELISA

ELISA Assay

Clinical and Research

Would you like to know more?

If you have any questions regarding our products or business, write to us here

Thank you!

You'll hear from us shortly.

An error occured!

Please try again, or contact us by e-mail if the problem persist.

Sign up for our newsletter

By signing up for our newsletter you will receive the latest news about our products.

Thank you!

You'll hear from us shortly.

An error occured!

Please try again, or contact us by e-mail if the problem persist.

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates